The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma.
We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [177Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025 Sep 25 [Epub ahead of print]
Vinay K Giri, Gerald M Kolodny, Marc B Garnick
Harvard Medical School, Boston, Massachusetts., Harvard Medical School, Boston, Massachusetts; .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40998725